866-997-4948(US-Canada Toll Free)

Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets

Published By :

GBI Research

Published Date : Aug 2011

Category :

Manufacturing, Packaging & Detailing

No. of Pages : 195 Pages


GBI Research, the leading business intelligence provider, has released its latest research, Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets, which provides insights regarding the comparative analysis of marketed drugs based on safety, efficacy, cost of therapy and total sales revenue. The report also delves deep into the descriptions of every marketed drug, discussing their safety, efficacy, cost of therapy and clinical studies.

The in-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Researchs team of experts.

GBI Researchs analysis showed that the marketed drugs had to score highly in terms of safety and efficacy to ensure maximum usage. Patents assisted some of the marketed drugs in generating sales revenue devoid of competition, with some seeking patent extensions as well to ensure additional returns. However, patent expiries have resulted in a decline in the cost of therapy and revenue for some of the marketed drugs.

Scope

  • Major indications with sizeable market share and growth.
  • Comparative analysis of major marketed drugs in each of the major indications, in terms of safety, efficacy, cost of therapy and total sales revenue of the drugs.
  • Detailed description of the drugs, including parameters such as safety, efficacy, cost of therapy and clinical studies.

Reasons to buy

The report will assist business development and help marketing executives to market products and strategize new product launches, by allowing them to - 

  • Differentiate their products from competitors in terms of safety, efficacy and cost of therapy.
  • Invest in research to achieve novelty in treatment with an acceptable safety and efficacy profile; and obtain patents for ensuring monopoly business.
  • Exploit licensing and acquisition opportunities by identifying products that might meet their expected returns.
  • Focus on the addition of new indications to the existing ones, and different dosage forms for patient compliance.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Build effective strategies to market their products.
  • Develop market-entry and market-expansion strategies by identifying the indications poised for strong growth.
Table of Contents

1 Table of Contents

1 Table of Contents 3
1.1 List of Tables 6

2 Comparative Analysis of Marketed Drugs in Major Indications Introduction 7
2.1 GBI Research Report Guidance 7

3 Comparative Analysis of Marketed Drugs in Major Indications Cardiovascular 8
3.1 Pulmonary Arterial Hypertension (PAH) 8
3.1.1 Comparative Analysis 8
3.1.2 Tracleer 12
3.1.3 Remodulin 14
3.1.4 Revatio 15
3.1.5 Letairis 17
3.1.6 Ventavis 18
3.1.7 Adcirca 19
3.2 Systemic Hypertension 21
3.2.1 Comparative Analysis 21
3.2.2 Diovan 24
3.2.3 Cozaar 25
3.2.4 Vasotec 26
3.2.5 Lotension 26
3.2.6 Norvasc 27
3.2.7 Plendil 28
3.2.8 Toprol-XL 28
3.2.9 Tenormin 29
3.3 Dyslipidemia 30
3.3.1 Comparative Analysis 30
3.3.2 Lipitor 34
3.3.3 Vytorin 35
3.3.4 Zetia 36
3.3.5 Trilipix 37
3.3.6 Simcor 37
3.3.7 Lescol 38
3.3.8 Livalo 39
3.3.9 Lovaza 40

4 Comparative Analysis of Marketed Drugs in Major Indications Metabolic Disorders 41
4.1 Type 2 diabetes 41
4.1.1 Comparative Analysis 41
4.1.2 Actos 43
4.1.3 Avandia 44
4.1.4 Januvia 45
4.1.5 Starlix 46
4.1.6 Byetta 47
4.1.7 Lantus 48
4.1.8 Levemir 48

5 Comparative Analysis of Marketed Drugs in Major Indications Gastrointestinal 50
5.1 Gastroesophageal Reflux Disease 50
5.1.1 Comparative Analysis 50
5.1.2 Protonix 54
5.1.3 Nexium 55
5.1.4 Aciphex 55
5.1.5 Prevacid 56
5.1.6 Prilosec 56
5.1.7 Tagamet 57
5.1.8 Pepcid 58
5.1.9 Zantac 58
5.1.10 Axid 59

6 Comparative Analysis of Marketed Drugs in Major Indications Musculoskeletal 60
6.1 Rheumatoid Arthritis (RA) 60
6.1.1 Comparative Analysis 60
6.1.2 Enbrel 63
6.1.3 Humira 64
6.1.4 Remicade 65
6.1.5 Rituxan 66
6.1.6 Celebrex 67
6.1.7 Orencia 67

7 Comparative Analysis of Marketed Drugs in Major Indications Central Nervous System 69
7.1 Schizophrenia 69
7.1.1 Comparative Analysis 69
7.1.2 Abilify 74
7.1.3 Geodon 75
7.1.4 Zyprexa 76
7.1.5 Seroquel 77
7.1.6 Invega 78
7.1.7 Invega Sustenna 80
7.1.8 Fanapt 81
7.1.9 Saphris 83
7.2 Epilepsy 85
7.2.1 Comparative Analysis 85
7.2.2 Lyrica 88
7.2.3 Gabitril 89
7.2.4 Banzel 90
7.2.5 Vimpat 91
7.2.6 Felbatol 92
7.2.7 Sabril 93
7.3 Alzheimers Disease 96
7.3.1 Comparative Analysis 96
7.3.2 Aricept 97
7.3.3 Exelon 98
7.3.4 Namenda 99
7.4 Parkinsons Disease (PD) 100
7.4.1 Comparative Analysis 100
7.4.2 Stalevo 102
7.4.3 Requip XL 103
7.4.4 Azilect 103
7.4.5 Mirapex 104

8 Comparative Analysis of Marketed Drugs in Major Indications Blood Disorders 106
8.1 Anemia 106
8.1.1 Comparative Analysis 106
8.1.2 Aranesp 108
8.1.3 Eprex 110
8.1.4 Venofer 111
8.1.5 Mircera 113
8.1.6 NeoRecormon 113

9 Comparative Analysis of Marketed Drugs in Major Indications Respiratory 115
9.1 Asthma 115
9.1.1 Comparative Analysis 115
9.1.2 Singulair 119
9.1.3 Accolate 120
9.1.4 Zyflo 121
9.1.5 Foradil Aerolizer 122
9.1.6 Symbicort 123
9.1.7 Xolair 124
9.1.8 Serevent Diskus 125
9.1.9 Advair Diskus 126
9.2 Chronic Obstructive Pulmonary Disorder (COPD) 129
9.2.1 Comparative Analysis 129
9.2.2 Spiriva Handihaler 132
9.2.3 Brovana 133
9.2.4 Foradil Aerolizer 134
9.2.5 Symbicort 135
9.2.6 Advair Diskus 136

10 Comparative Analysis of Marketed Drugs in Major Indications Oncology 138
10.1 Breast Cancer 138
10.1.1 Comparative Analysis 138
10.1.2 Abraxane 142
10.1.3 Arimidex 144
10.1.4 Femara 145
10.1.5 Herceptin 147
10.1.6 Taxotere 148
10.1.7 Xeloda 150
10.1.8 Tykerb 151
10.1.9 Avastin 152
10.2 Non-Hodgkins Lymphoma 154
10.2.1 Comparative Analysis 154
10.2.2 Rituxan 156
10.2.3 Velcade 158
10.2.4 Bexxar 159
10.2.5 Zevalin 161
10.2.6 Treanda 162
10.3 Prostate Cancer 165
10.3.1 Comparative Analysis 165
10.3.2 Taxotere 169
10.3.3 Casodex 170
10.3.4 Provenge 172
10.3.5 Eligard 174
10.3.6 Firmagon 174
10.3.7 Decapeptyl SR 176
10.4 Non-Small Cell Lung Cancer (NSCLC) 177
10.4.1 Comparative Analysis 177
10.4.2 Alimta 180
10.4.3 Avastin 181
10.4.4 Gemzar 182
10.4.5 Iressa 184
10.4.6 Tarceva 185
10.4.7 Taxotere 186

11 Comparative Analysis of Marketed Drugs in Major Indications Conclusion 188

12 Comparative Analysis of Marketed Drugs in Major Indications Appendix 189
12.1 Market Definitions 189
12.2 Abbreviations 189
12.3 Research Methodology 193
12.3.1 Coverage 193
12.3.2 Secondary Research 193
12.3.3 Primary Research 194
12.3.4 Expert Panel Validation 194
12.4 Contact Us 194
12.5 Disclaimer 194
12.6 Sources 195

List of Table


Table 1: Comparative Analysis of Marketed Drugs, Pulmonary Arterial Hypertension, 2011 8
Table 2: Comparative Analysis of Marketed Drugs, Systemic Hypertension, 2011 21
Table 3: Comparative Analysis of Marketed Drugs, Systemic Hypertension, 2011 22
Table 4: Comparative Analysis of Marketed Drugs, Dyslipidemia, 2011 30
Table 5: Comparative Analysis of Marketed Drugs, Dyslipidemia, 2011 32
Table 6: Comparative Analysis of Marketed Drugs, Type 2 diabetes, 2011 41
Table 7: Comparative Analysis of Marketed Drugs, Gastroesophageal Reflux Disease, 2011 50
Table 8: Comparative Analysis of Marketed Drugs, Gastroesophageal Reflux Disease, 2011 52
Table 9: Comparative Analysis of Marketed Drugs, Rheumatoid Arthritis, 2011 60
Table 10: Comparative Analysis of Marketed Drugs, Schizophrenia, 2011 69
Table 11: Comparative Analysis of Marketed Drugs, Schizophrenia, 2011 71
Table 12: Comparative Analysis of Marketed Drugs, Epilepsy, 2011 85
Table 13: Comparative Analysis of Marketed Drugs, Alzheimer\'s Disease, 2011 96
Table 14: Comparative Analysis of Marketed Drugs, Parkinsons Disease, 2011 100
Table 15: Comparative Analysis of Marketed Drugs, Anemia, 2011 106
Table 16: Comparative Analysis of Marketed Drugs, Asthma, 2011 115
Table 17: Comparative Analysis of Marketed Drugs, Asthma, 2011 117
Table 18: Comparative Analysis of Marketed Drugs, Chronic Obstructive Pulmonary Disorder, 2011 129
Table 19: Comparative Analysis of Marketed Drugs, Breast Cancer, 2011 138
Table 20: Comparative Analysis of Marketed Drugs, Breast Cancer, 2011 140
Table 21: Comparative Analysis of Marketed Drugs, Non-Hodgkins Lymphoma, 2011 154
Table 22: Comparative Analysis of Marketed Drugs, Prostate Cancer, 2011 165
Table 23: Comparative Analysis of Marketed Drugs, Non-Small Cell Lung Cancer, 2011 177

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *